🇺🇸 FDA
Patent

US 8664254

Dual-acting imidazole antihypertensive agents

granted A61KA61K31/415A61K31/4164

Quick answer

US patent 8664254 (Dual-acting imidazole antihypertensive agents) held by Theravance, Inc. expires Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Mar 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/415, A61K31/4164, A61K31/417, A61K31/4188